SidaGhanaV1, Main, Exploration, bibRecord, 000C22

Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2

Identifieur interne : 000C22 ( Main/Exploration ); précédent : 000C21; suivant : 000C23

Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2

Auteurs : Jérome Legoff [France] ; Philippe Mayaud [Royaume-Uni] ; Gérard Gresenguet [Afrique du Sud] ; Helen A. Weiss [Royaume-Uni] ; Khonde Nzambi [Ghana] ; Eric Frost [Canada] ; Jacques Pepin [Canada] ; Laurent Belec [France]

Source :

Journal of clinical microbiology : (Print) [ 0095-1137 ] ; 2008.

RBID : Pascal:08-0307437

Descripteurs français

KwdFr :
- ADN viral (analyse), ADN viral (isolement et purification), Aciclovir (administration et posologie), Aciclovir (usage thérapeutique), Anticorps antiviraux (sang), Antiviraux (administration et posologie), Antiviraux (usage thérapeutique), Femelle, Ghana (épidémiologie), Herpès génital (diagnostic), Herpès génital (traitement médicamenteux), Herpès génital (virologie), Herpès génital (épidémiologie), Herpèsvirus humain de type 2 (génétique), Herpèsvirus humain de type 2 (immunologie), Herpèsvirus humain de type 2 (isolement et purification), Humains, Protéines de l'enveloppe virale (immunologie), Réaction de polymérisation en chaîne (), République centrafricaine (épidémiologie), Sensibilité et spécificité, Test ELISA (), Trousses de réactifs pour diagnostic.
MESH :
- administration et posologie : Aciclovir, Antiviraux.
- analyse : ADN viral.
- diagnostic : Herpès génital.
- génétique : Herpèsvirus humain de type 2.
- immunologie : Herpèsvirus humain de type 2, Protéines de l'enveloppe virale.
- isolement et purification : ADN viral, Herpèsvirus humain de type 2.
- sang : Anticorps antiviraux.
- traitement médicamenteux : Herpès génital.
- usage thérapeutique : Aciclovir, Antiviraux.
- virologie : Herpès génital.
- épidémiologie : Ghana, Herpès génital, République centrafricaine.
Pascal (Inist)
- Femelle, Herpesvirus hominis 2, Détection, Anticorps, Humains, Microbiologie, Réaction de polymérisation en chaîne, Sensibilité et spécificité, Test ELISA, Trousses de réactifs pour diagnostic.
Wicri :
- geographic : Ghana, République centrafricaine.

English descriptors

KwdEn :
- Acyclovir (administration & dosage), Acyclovir (therapeutic use), Antibodies, Viral (blood), Antibody, Antiviral Agents (administration & dosage), Antiviral Agents (therapeutic use), Central African Republic (epidemiology), DNA, Viral (analysis), DNA, Viral (isolation & purification), Detection, Enzyme-Linked Immunosorbent Assay (methods), Female, Ghana (epidemiology), Herpes Genitalis (diagnosis), Herpes Genitalis (drug therapy), Herpes Genitalis (epidemiology), Herpes Genitalis (virology), Herpesvirus 2, Human (genetics), Herpesvirus 2, Human (immunology), Herpesvirus 2, Human (isolation & purification), Human herpesvirus 2, Humans, Microbiology, Polymerase Chain Reaction (methods), Reagent Kits, Diagnostic, Sensitivity and Specificity, Viral Envelope Proteins (immunology).
MESH :
- chemical , administration & dosage : Acyclovir, Antiviral Agents.
- chemical , analysis : DNA, Viral.
- chemical , blood : Antibodies, Viral.
- chemical , immunology : Viral Envelope Proteins.
- chemical , isolation & purification : DNA, Viral.
- chemical , therapeutic use : Acyclovir, Antiviral Agents.
- geographic , epidemiology : Central African Republic, Ghana.
- diagnosis : Herpes Genitalis.
- drug therapy : Herpes Genitalis.
- epidemiology : Herpes Genitalis.
- genetics : Herpesvirus 2, Human.
- immunology : Herpesvirus 2, Human.
- isolation & purification : Herpesvirus 2, Human.
- methods : Enzyme-Linked Immunosorbent Assay, Polymerase Chain Reaction.
- virology : Herpes Genitalis.
- Female, Humans, Reagent Kits, Diagnostic, Sensitivity and Specificity.

Abstract

The performances of commercial enzyme-linked immunosorbent assays (ELISAs) in detecting herpes simplex virus type 2 (HSV-2) antibodies have been inconsistent for African and human immunodeficiency virus (HIV)-positive populations. We compared the performances of the HerpeSelect and Kalon glycoprotein G2 ELISAs for patients with genital ulcer disease in Ghana and the Central African Republic. Sera from 434 women were tested with the HerpeSelect assay, and a subsample (n = 199) was tested by the Kalon assay. Ulcer swabs and cervicovaginal lavage samples were tested for HSV-2 DNA by PCR. HSV-2-seronegative women with detectable genital HSV-2 DNA were retested for HSV-2 antibodies 14 and 28 days later by the two ELISAs. A total of 346 (80%) women were positive by HerpeSelect at baseline, and 225 (54%) had detectable genital (lesional or cervicovaginal) HSV-2 DNA. Sixty-six (19%) HerpeSelect-positive samples had low-positive index values (1.1 to 3.5), and 58% of these samples had detectable genital HSV-2 DNA. Global agreement between the two serological assays was 86%. Concordance was high (99%) for sera that were negative by HerpeSelect or had high index values (>3.5). Defining infection detected by HSV-2 DNA PCR and/or Kalon assay as true infection, 71% of sera with low-positive index values were associated with true HSV-2 infection. Twenty-five women were identified as having nonprimary first-episode genital HSV-2 infection. Rates of HSV-2 seroconversion at day 14 were 77% (10/13 patients) by HerpeSelect assay and 23% (3/13 patients) by Kalon assay, with four additional seroconversions detected by Kalon assay at day 28. HIV serostatus did not influence assay performance. Low index values obtained with the HerpeSelect assay may correspond to true HSV-2 infection, in particular to nonprimary first episodes of genital HSV-2 infection, and need to be interpreted in the context of clinical history.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446869

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2</title>
<author><name sortKey="Legoff, Jerome" sort="Legoff, Jerome" uniqKey="Legoff J" first="Jérome" last="Legoff">Jérome Legoff</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centres de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris-Descartes</orgName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Laboratoire de Microbiologie, Hôpital Saint-Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mayaud, Philippe" sort="Mayaud, Philippe" uniqKey="Mayaud P" first="Philippe" last="Mayaud">Philippe Mayaud</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Clinical Research Unit, Department of Infectious and Tropical Diseases, and Infectious Diseases Epidemiology Unit, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gresenguet, Gerard" sort="Gresenguet, Gerard" uniqKey="Gresenguet G" first="Gérard" last="Gresenguet">Gérard Gresenguet</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Centre National de Référence des Maladies Sexuellement Transmissibles et du SIDA de Bangui and Unité de Recherches et d'lntervention sur les Maladies Sexuellement Transmissibles et du SIDA, Faculté des Sciences de la Santé</s1>
<s2>Bangui</s2>
<s3>ZAF</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Afrique du Sud</country>
<wicri:noRegion>Bangui</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Weiss, Helen A" sort="Weiss, Helen A" uniqKey="Weiss H" first="Helen A." last="Weiss">Helen A. Weiss</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Clinical Research Unit, Department of Infectious and Tropical Diseases, and Infectious Diseases Epidemiology Unit, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nzambi, Khonde" sort="Nzambi, Khonde" uniqKey="Nzambi K" first="Khonde" last="Nzambi">Khonde Nzambi</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>West African Project To Combat AIDS and STDs</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frost, Eric" sort="Frost, Eric" uniqKey="Frost E" first="Eric" last="Frost">Eric Frost</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Centre for International Health, University of Sherbrooke</s1>
<s2>Sherbrooke</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Sherbrooke</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pepin, Jacques" sort="Pepin, Jacques" uniqKey="Pepin J" first="Jacques" last="Pepin">Jacques Pepin</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Centre for International Health, University of Sherbrooke</s1>
<s2>Sherbrooke</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Sherbrooke</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Belec, Laurent" sort="Belec, Laurent" uniqKey="Belec L" first="Laurent" last="Belec">Laurent Belec</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centres de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris-Descartes</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0307437</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0307437 INIST</idno>
<idno type="RBID">Pascal:08-0307437</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000071</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000069</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000058</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000058</idno>
<idno type="wicri:doubleKey">0095-1137:2008:Legoff J:performance:of:herpeselect</idno>
<idno type="wicri:Area/Main/Merge">000C45</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2446869</idno>
<idno type="RBID">PMC:2446869</idno>
<idno type="wicri:Area/Pmc/Corpus">000196</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000196</idno>
<idno type="wicri:Area/Pmc/Curation">000195</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000195</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000462</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000462</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">000669</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000669</idno>
<idno type="wicri:Area/PubMed/Curation">000669</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000669</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000669</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000669</idno>
<idno type="wicri:Area/Ncbi/Merge">000276</idno>
<idno type="wicri:Area/Ncbi/Curation">000276</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000276</idno>
<idno type="wicri:doubleKey">0095-1137:2008:Legoff J:performance:of:herpeselect</idno>
<idno type="wicri:Area/Main/Merge">000B53</idno>
<idno type="wicri:Area/Main/Curation">000C22</idno>
<idno type="wicri:Area/Main/Exploration">000C22</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2</title>
<author><name sortKey="Legoff, Jerome" sort="Legoff, Jerome" uniqKey="Legoff J" first="Jérome" last="Legoff">Jérome Legoff</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centres de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris-Descartes</orgName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Laboratoire de Microbiologie, Hôpital Saint-Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mayaud, Philippe" sort="Mayaud, Philippe" uniqKey="Mayaud P" first="Philippe" last="Mayaud">Philippe Mayaud</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Clinical Research Unit, Department of Infectious and Tropical Diseases, and Infectious Diseases Epidemiology Unit, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gresenguet, Gerard" sort="Gresenguet, Gerard" uniqKey="Gresenguet G" first="Gérard" last="Gresenguet">Gérard Gresenguet</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Centre National de Référence des Maladies Sexuellement Transmissibles et du SIDA de Bangui and Unité de Recherches et d'lntervention sur les Maladies Sexuellement Transmissibles et du SIDA, Faculté des Sciences de la Santé</s1>
<s2>Bangui</s2>
<s3>ZAF</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Afrique du Sud</country>
<wicri:noRegion>Bangui</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Weiss, Helen A" sort="Weiss, Helen A" uniqKey="Weiss H" first="Helen A." last="Weiss">Helen A. Weiss</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Clinical Research Unit, Department of Infectious and Tropical Diseases, and Infectious Diseases Epidemiology Unit, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nzambi, Khonde" sort="Nzambi, Khonde" uniqKey="Nzambi K" first="Khonde" last="Nzambi">Khonde Nzambi</name>
<affiliation wicri:level="3"><inist:fA14 i1="06"><s1>West African Project To Combat AIDS and STDs</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
<placeName><settlement type="city">Accra</settlement>
<region nuts="2">Région du Grand Accra</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Frost, Eric" sort="Frost, Eric" uniqKey="Frost E" first="Eric" last="Frost">Eric Frost</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Centre for International Health, University of Sherbrooke</s1>
<s2>Sherbrooke</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Sherbrooke</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pepin, Jacques" sort="Pepin, Jacques" uniqKey="Pepin J" first="Jacques" last="Pepin">Jacques Pepin</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Centre for International Health, University of Sherbrooke</s1>
<s2>Sherbrooke</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Sherbrooke</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Belec, Laurent" sort="Belec, Laurent" uniqKey="Belec L" first="Laurent" last="Belec">Laurent Belec</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centres de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris-Descartes</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical microbiology : (Print)</title>
<title level="j" type="abbreviated">J. clin. microbiol. : (Print)</title>
<idno type="ISSN">0095-1137</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical microbiology : (Print)</title>
<title level="j" type="abbreviated">J. clin. microbiol. : (Print)</title>
<idno type="ISSN">0095-1137</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acyclovir (administration & dosage)</term>
<term>Acyclovir (therapeutic use)</term>
<term>Antibodies, Viral (blood)</term>
<term>Antibody</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Central African Republic (epidemiology)</term>
<term>DNA, Viral (analysis)</term>
<term>DNA, Viral (isolation & purification)</term>
<term>Detection</term>
<term>Enzyme-Linked Immunosorbent Assay (methods)</term>
<term>Female</term>
<term>Ghana (epidemiology)</term>
<term>Herpes Genitalis (diagnosis)</term>
<term>Herpes Genitalis (drug therapy)</term>
<term>Herpes Genitalis (epidemiology)</term>
<term>Herpes Genitalis (virology)</term>
<term>Herpesvirus 2, Human (genetics)</term>
<term>Herpesvirus 2, Human (immunology)</term>
<term>Herpesvirus 2, Human (isolation & purification)</term>
<term>Human herpesvirus 2</term>
<term>Humans</term>
<term>Microbiology</term>
<term>Polymerase Chain Reaction (methods)</term>
<term>Reagent Kits, Diagnostic</term>
<term>Sensitivity and Specificity</term>
<term>Viral Envelope Proteins (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ADN viral (analyse)</term>
<term>ADN viral (isolement et purification)</term>
<term>Aciclovir (administration et posologie)</term>
<term>Aciclovir (usage thérapeutique)</term>
<term>Anticorps antiviraux (sang)</term>
<term>Antiviraux (administration et posologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Femelle</term>
<term>Ghana (épidémiologie)</term>
<term>Herpès génital (diagnostic)</term>
<term>Herpès génital (traitement médicamenteux)</term>
<term>Herpès génital (virologie)</term>
<term>Herpès génital (épidémiologie)</term>
<term>Herpèsvirus humain de type 2 (génétique)</term>
<term>Herpèsvirus humain de type 2 (immunologie)</term>
<term>Herpèsvirus humain de type 2 (isolement et purification)</term>
<term>Humains</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Réaction de polymérisation en chaîne ()</term>
<term>République centrafricaine (épidémiologie)</term>
<term>Sensibilité et spécificité</term>
<term>Test ELISA ()</term>
<term>Trousses de réactifs pour diagnostic</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Acyclovir</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>DNA, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>DNA, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acyclovir</term>
<term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Central African Republic</term>
<term>Ghana</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Aciclovir</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>ADN viral</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Herpes Genitalis</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Herpès génital</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Herpes Genitalis</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Herpes Genitalis</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Herpesvirus 2, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Herpèsvirus humain de type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Herpèsvirus humain de type 2</term>
<term>Protéines de l'enveloppe virale</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Herpesvirus 2, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Herpesvirus 2, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>ADN viral</term>
<term>Herpèsvirus humain de type 2</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Enzyme-Linked Immunosorbent Assay</term>
<term>Polymerase Chain Reaction</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Herpès génital</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Aciclovir</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Herpès génital</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Herpes Genitalis</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Ghana</term>
<term>Herpès génital</term>
<term>République centrafricaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Reagent Kits, Diagnostic</term>
<term>Sensitivity and Specificity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Femelle</term>
<term>Herpesvirus hominis 2</term>
<term>Détection</term>
<term>Anticorps</term>
<term>Humains</term>
<term>Microbiologie</term>
<term>Réaction de polymérisation en chaîne</term>
<term>Sensibilité et spécificité</term>
<term>Test ELISA</term>
<term>Trousses de réactifs pour diagnostic</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term>
<term>République centrafricaine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The performances of commercial enzyme-linked immunosorbent assays (ELISAs) in detecting herpes simplex virus type 2 (HSV-2) antibodies have been inconsistent for African and human immunodeficiency virus (HIV)-positive populations. We compared the performances of the HerpeSelect and Kalon glycoprotein G2 ELISAs for patients with genital ulcer disease in Ghana and the Central African Republic. Sera from 434 women were tested with the HerpeSelect assay, and a subsample (n = 199) was tested by the Kalon assay. Ulcer swabs and cervicovaginal lavage samples were tested for HSV-2 DNA by PCR. HSV-2-seronegative women with detectable genital HSV-2 DNA were retested for HSV-2 antibodies 14 and 28 days later by the two ELISAs. A total of 346 (80%) women were positive by HerpeSelect at baseline, and 225 (54%) had detectable genital (lesional or cervicovaginal) HSV-2 DNA. Sixty-six (19%) HerpeSelect-positive samples had low-positive index values (1.1 to 3.5), and 58% of these samples had detectable genital HSV-2 DNA. Global agreement between the two serological assays was 86%. Concordance was high (99%) for sera that were negative by HerpeSelect or had high index values (>3.5). Defining infection detected by HSV-2 DNA PCR and/or Kalon assay as true infection, 71% of sera with low-positive index values were associated with true HSV-2 infection. Twenty-five women were identified as having nonprimary first-episode genital HSV-2 infection. Rates of HSV-2 seroconversion at day 14 were 77% (10/13 patients) by HerpeSelect assay and 23% (3/13 patients) by Kalon assay, with four additional seroconversions detected by Kalon assay at day 28. HIV serostatus did not influence assay performance. Low index values obtained with the HerpeSelect assay may correspond to true HSV-2 infection, in particular to nonprimary first episodes of genital HSV-2 infection, and need to be interpreted in the context of clinical history.</div>
</front>
</TEI>
<affiliations><list><country><li>Afrique du Sud</li>
<li>Canada</li>
<li>France</li>
<li>Ghana</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
<li>Région du Grand Accra</li>
<li>Île-de-France</li>
</region>
<settlement><li>Accra</li>
<li>Londres</li>
<li>Paris</li>
</settlement>
<orgName><li>Université Paris-Descartes</li>
</orgName>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Legoff, Jerome" sort="Legoff, Jerome" uniqKey="Legoff J" first="Jérome" last="Legoff">Jérome Legoff</name>
</region>
<name sortKey="Belec, Laurent" sort="Belec, Laurent" uniqKey="Belec L" first="Laurent" last="Belec">Laurent Belec</name>
<name sortKey="Legoff, Jerome" sort="Legoff, Jerome" uniqKey="Legoff J" first="Jérome" last="Legoff">Jérome Legoff</name>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Mayaud, Philippe" sort="Mayaud, Philippe" uniqKey="Mayaud P" first="Philippe" last="Mayaud">Philippe Mayaud</name>
</region>
<name sortKey="Mayaud, Philippe" sort="Mayaud, Philippe" uniqKey="Mayaud P" first="Philippe" last="Mayaud">Philippe Mayaud</name>
<name sortKey="Weiss, Helen A" sort="Weiss, Helen A" uniqKey="Weiss H" first="Helen A." last="Weiss">Helen A. Weiss</name>
<name sortKey="Weiss, Helen A" sort="Weiss, Helen A" uniqKey="Weiss H" first="Helen A." last="Weiss">Helen A. Weiss</name>
</country>
<country name="Afrique du Sud"><noRegion><name sortKey="Gresenguet, Gerard" sort="Gresenguet, Gerard" uniqKey="Gresenguet G" first="Gérard" last="Gresenguet">Gérard Gresenguet</name>
</noRegion>
</country>
<country name="Ghana"><region name="Région du Grand Accra"><name sortKey="Nzambi, Khonde" sort="Nzambi, Khonde" uniqKey="Nzambi K" first="Khonde" last="Nzambi">Khonde Nzambi</name>
</region>
</country>
<country name="Canada"><noRegion><name sortKey="Frost, Eric" sort="Frost, Eric" uniqKey="Frost E" first="Eric" last="Frost">Eric Frost</name>
</noRegion>
<name sortKey="Pepin, Jacques" sort="Pepin, Jacques" uniqKey="Pepin J" first="Jacques" last="Pepin">Jacques Pepin</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C22 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000C22 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaGhanaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:08-0307437
   |texte=   Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2
}}

This area was generated with Dilib version V0.6.31.
Data generation: Tue Nov 7 18:07:38 2017. Site generation: Tue Mar 5 15:01:57 2024

Le SIDA au Ghana (serveur d'exploration)

Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2

Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Le SIDA au Ghana (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.